TransCelerate is a consortium of 19 major pharmaceutical companies, which shares clinical development information among its members. Its subsidiary BioCelerate focuses on sharing information preclinical development information.
The creation of DataCelerate combines both sets of data with the addition of TransCelerate’s Placebo and Standard of Care (PSoC) data repository to be migrated into DataCelerate. The addition expands the data volume to include more than 85,000 patients and more than 130 studies in nearly 20 therapeutic areas.
Dalavir Gill, CEO of Transcelerate, told us that DataCelerate’s key is providing patient-level data that is de-identified and anonymous.
“[The data] is much more granular, and that’s what we’re hearing from the companies that are using the data. Because its patient-level data its value is incredibly advanced,” said Gill.
Behind the creation of DataCelerate is the idea that data is often only accessed by publications or at conferences, but the information accessible through DataCelerate is that from companies which can then be shared across the consortium.
Multiple de-identified research and development data types can be submitted, uploaded, converted, harmonized, and downloaded through a secured environment via the platform.
Gill said, “The beauty of that, if it sits in one platform, that data will eventually connect,” furthering, “It’s when that data connect in the future it will generate additional value.”
TransCelerate has previously launched initiatives to accelerate clinical trials, citing the use of data sharing to decrease cumulative trial execution.
The ability to share data will theoretically allow clinical trials to be addressed differently. “In many cases they’ve [those with access to datasets] been able to do the clinical trials with a lot less patients needed then if they did not have the information,” said Gill.
“We also know that you can avoid observational studies because you now have real-world clinical data from other trials,” he said. “We also have cases were companies have been able to construct and reconstruct endpoints because now they have information that they previously did not have.”
Gill also said that the quantitative value of DataCelerate is a more efficiently run clinical trial with fewer patients participating, “in my opinion, that’s an obligation we all have to reduce the number of patients that have to participate in what is, after all, an experiment – a clinical trial.”
DataCelerate is currently available only to TransCelerate and BioCelerate member companies.